Pegah Farrokhi

4.0k total citations
6 papers, 63 citations indexed

About

Pegah Farrokhi is a scholar working on Pathology and Forensic Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Pegah Farrokhi has authored 6 papers receiving a total of 63 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pathology and Forensic Medicine, 3 papers in Oncology and 2 papers in Gastroenterology. Recurrent topics in Pegah Farrokhi's work include Gastrointestinal Tumor Research and Treatment (2 papers), Lymphoma Diagnosis and Treatment (2 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Pegah Farrokhi is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (2 papers), Lymphoma Diagnosis and Treatment (2 papers) and Pancreatic and Hepatic Oncology Research (1 paper). Pegah Farrokhi collaborates with scholars based in Iran, United States and Brazil. Pegah Farrokhi's co-authors include Mehran Sharifi, N Frénoy, Emma Goldschmidt, Béatrice Delmas-Marsalet, D. Machover, Alireza Sadeghi, Françoise Norol, Ayhan Ulusakarya, Catherine Guettier and C Jasmin and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and DARU Journal of Pharmaceutical Sciences.

In The Last Decade

Pegah Farrokhi

4 papers receiving 62 citations

Peers

Pegah Farrokhi

PFM

GENET

ONCOL

PRM

NEURO

Amanda Gillespie-Twardy United States

Sandra Le Guyader-Peyrou France

Simon Rule United Kingdom

Gavin Preston United Kingdom

Riccardo Bruna Italy

Francisco Lastiri Argentina

Katarzyna Domańska‐Czyż Poland

Lukas Kazianka Austria

Magda Alexis France

Khalid Hirmiz Canada

Amanda Gillespie-Twardy United States

Pegah Farrokhi

23 ×0.6

PFM

18 ×0.7

GENET

23 ×1.0

ONCOL

8 ×0.5

PRM

5 ×0.6

NEURO

Citations per year, relative to Pegah Farrokhi Pegah Farrokhi (= 1×) peers Amanda Gillespie-Twardy

Countries citing papers authored by Pegah Farrokhi

Since Specialization

Citations

This map shows the geographic impact of Pegah Farrokhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pegah Farrokhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pegah Farrokhi more than expected).

Fields of papers citing papers by Pegah Farrokhi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pegah Farrokhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pegah Farrokhi. The network helps show where Pegah Farrokhi may publish in the future.

Co-authorship network of co-authors of Pegah Farrokhi

This figure shows the co-authorship network connecting the top 25 collaborators of Pegah Farrokhi. A scholar is included among the top collaborators of Pegah Farrokhi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pegah Farrokhi. Pegah Farrokhi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Tan, Chia Jie, et al.. (2025). Cost-effectiveness of NALIRIFOX compared to other first-line treatments for metastatic pancreatic cancer.. Journal of Clinical Oncology. 43(4_suppl). 733–733.

2.

Farrokhi, Pegah, et al.. (2022). Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis. DARU Journal of Pharmaceutical Sciences. 30(2). 367–378. 8 indexed citations

3.

Sadeghi, Alireza, et al.. (2022). Melatonin in the prevention of cisplatin-induced acute nephrotoxicity. Research in Pharmaceutical Sciences. 17(2). 176–188. 12 indexed citations

4.

Farrokhi, Pegah, et al.. (2022). Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east. Research in Pharmaceutical Sciences. 17(6). 621–634. 6 indexed citations

5.

Farrokhi, Pegah, et al.. (2022). Evaluation of FLANG versus mitoxantrone and etoposide for the treatment of refractory/relapsed acute leukemia. Immunopathologia Persa.

6.

Machover, D., Béatrice Delmas-Marsalet, Emma Goldschmidt, et al.. (2001). Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin’s lymphoma. Annals of Oncology. 12(10). 1439–1443. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact